CSIFX
Price
$46.49
Change
-$0.23 (-0.49%)
Updated
Nov 14 closing price
RLBGX
Price
$36.49
Change
-$0.17 (-0.46%)
Updated
Nov 14 closing price
Ad is loading...

CSIFX vs RLBGX

Header iconCSIFX vs RLBGX Comparison
Open Charts CSIFX vs RLBGXBanner chart's image
Calvert Balanced A
Price$46.49
Change-$0.23 (-0.49%)
VolumeN/A
CapitalizationN/A
American Funds American Balanced R6
Price$36.49
Change-$0.17 (-0.46%)
VolumeN/A
CapitalizationN/A
CSIFX vs RLBGX Comparison Chart
Loading...
View a ticker or compare two or three
VS
CSIFX vs. RLBGX commentary
Nov 15, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CSIFX is a Buy and RLBGX is a StrongBuy.

FUNDAMENTALS
Fundamentals
RLBGX has more cash in the bank: 239B vs. CSIFX (1.34B). RLBGX pays higher dividends than CSIFX: RLBGX (2.55) vs CSIFX (2.23). CSIFX was incepted earlier than RLBGX: CSIFX (42 years) vs RLBGX (16 years). RLBGX is a more actively managed with annual turnover of: 171.00 vs. CSIFX (106.00). RLBGX has a lower initial minimum investment than CSIFX: RLBGX (250) vs CSIFX (1000). CSIFX annual gain was more profitable for investors over the last year : 26.50 vs. RLBGX (23.04). CSIFX return over 5 years is better than : 43.02 vs. RLBGX (38.63).
CSIFXRLBGXCSIFX / RLBGX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence42 years16 years-
Gain YTD20.21515.935127%
Front LoadN/AN/A-
Min. Initial Investment1000250400%
Min. Initial Investment IRAN/AN/A-
Net Assets1.34B239B1%
Annual Yield % from dividends2.232.5587%
Returns for 1 year26.5023.04115%
Returns for 3 years10.8112.7785%
Returns for 5 years43.0238.63111%
Returns for 10 years57.6256.10103%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RARE48.720.88
+1.84%
Ultragenyx Pharmaceutical
BCS13.21-0.01
-0.08%
Barclays PLC
PUBM16.27-0.15
-0.94%
PubMatic
MRKR3.64-0.08
-2.15%
Marker Therapeutics
EDAP2.55-0.09
-3.41%
EDAP TMS SA